达那唑治疗月经过多的临床及内分泌研究的初步结果。

Preliminary results on clinical and endocrine studies in the treatment of menorrhagia with danazol.

作者信息

Chimbira T H, Anderson A B, Cope E, Turnbull A C

出版信息

Postgrad Med J. 1979;55 Suppl 5:90-4.

Abstract

Preliminary results are presented on the effect of 400, 200 and 100 mg of daily danazol on measured menstrual blood loss, in women with menorrhagia. Both 400 and 200 mg daily effectively suppressed menstrual blood loss, 400 mg reducing menstrual blood loss from a pretreatment mean of 456 +/- 48 ml to 45 +/- 26 ml and 6 +/- 5 ml during the second and third months of treatment. Menstrual blood loss on 100 mg danazol was only minimally reduced. After two to three months on danazol, the pituitary showed ability to respond to gonadotrophin releasing hormone and to oestradiol benzoate. A lack of effect of danazol on most coagulation and fibrinolytic factors was demonstrated.

摘要

本文呈现了每日服用400毫克、200毫克和100毫克达那唑对月经过多女性经量测定影响的初步结果。每日400毫克和200毫克的剂量均能有效抑制经量，400毫克剂量可使经量从治疗前平均456±48毫升在治疗的第二个月和第三个月分别降至45±26毫升和6±5毫升。100毫克达那唑对经量的减少作用甚微。服用达那唑两到三个月后，垂体显示出对促性腺激素释放激素和苯甲酸雌二醇有反应的能力。研究表明达那唑对大多数凝血和纤溶因子没有影响。